This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 11, 2018.(b)(4).The returned sample was visually inspected no obvious anomaly, such as break were found.After having been rinsed and dried, the unit was tested for its oxygen (o2) transfer volume and carbon dioxide (co2) removal volume in accordance with the factory's shipping inspection protocol and verified that the actual sample was the normal product with no issue in the gas transfer performance.With the absence of the involved pump record to be evaluated or the detailed information about the events leading up to this complaint, it is difficult to determine the definitive cause of this complaint.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|